You are here

Methodology Study To Examine 6-Week Food Intake With Liraglutide In Obese Subjects

Last updated on May 10, 2018

FOR MORE INFORMATION
Study Location
Translational Research Institute for Metabolism and Diabetes
Orlando, Florida, 32804 United States
Contact
1-800-718-1021
Eligibility criteria
Condition
The disease, disorder, syndrome, illness, or injury that is being studied.
Obesity
Sex
Females and Males
Age
Pediatric Trials: 0-17 Years
Adult Trials: 18+ Years
18-75 years
Inclusion criteria
The factors, or reasons, that allow a person to participate in a clinical study.
Show details

- Males and female subjects;

- Body Mass Index 30-40 kg/m2;

Exclusion criteria
The factors, or reasons, that prevent a person from participating in a clinical study.
Show details

- Evidence of history of clinically significant hematological, renal, endocrine,
pulmonary, gastrointestinal, cardiovascular, hepatic, psychiatric, neurologic, or
allergic disease (including drug allergises, but excluding untreated, asymptomatic,
seasonal allergies at time of dosing)

NCT03041792
Pfizer
Completed
Methodology Study To Examine 6-Week Food Intake With Liraglutide In Obese Subjects

NEED INFO?

Questions about a trial? Call or email to reach a Pfizer Clinical Trial Contact Center

Pfizer Clinical Trials Contact Center

1-800-718-1021

[email protected]

call now

Try a new search

Search for Clinical Trials by condition, keyword or trial number. Share your location or enter your zip code, city, or country to find studies near you.

Similar Trials

Obesity
NCT00367783
All Genders
18+
Years
Multiple Sites
Morbid Obesity, Metabolic Disease
NCT00283374
All Genders
18+
Years
Multiple Sites
Methodology Study To Examine 6-Week Food Intake With Liraglutide In Obese Subjects
A 6-week, Randomized, Double-blind, Placebo-controlled, Two-arm, Parallel Methodology Study To Assess The Effect Of Liraglutide On Food Intake In Obese Subjects
This will be a randomized, double blind, placebo controlled, 2 arm, parallel group, methodology study to assess the effect of 6 weeks of liraglutide administration on food intake in obese subjects.
Not Provided
Interventional
Phase 1
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double (Participant, Investigator)
Primary Purpose: Basic Science
Obesity
  • Drug: Liraglutide
    Liraglutide
  • Other: Placebo
    Placebo
  • Experimental: Active
    Liraglutide
    Intervention: Drug: Liraglutide
  • Placebo Comparator: Placebo
    Placebo comparator
    Intervention: Other: Placebo
Not Provided


*   Includes publications given by the data provider as well as publications
identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Recruiting
60
January 16, 2018
January 16, 2018   (Final data collection date for primary outcome measure)

Inclusion Criteria:

  • Males and female subjects;
  • Body Mass Index 30-40 kg/m2;

Exclusion Criteria:

  • Evidence of history of clinically significant hematological, renal, endocrine, pulmonary, gastrointestinal, cardiovascular, hepatic, psychiatric, neurologic, or allergic disease (including drug allergises, but excluding untreated, asymptomatic, seasonal allergies at time of dosing)
Sexes Eligible for Study: All
18 Years to 75 Years   (Adult, Senior)
Yes

Contact: Pfizer CT.gov Call Center 1-800-718-1021 [email protected]
United States
 
 
NCT03041792
A9001498
No
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
Plan to Share IPD: No
Plan Description: Information relating to our policy on data sharing and the process for requesting data can be found at the following link: http://www.pfizer.com/research/clinical_trials/trial_data_and_results/da...
Pfizer
Pfizer
Not Provided
Study Director: Pfizer CT.gov Call Center Pfizer
Pfizer
November 2017

ICMJE     Data element required by the

International Committee of Medical Journal Editors
and the
World Health Organization ICTRP

FOR MORE INFORMATION

Contact a representative by phone, email, or visiting thte study website. To get updates and notications about this trail, sign up using the form below.

BY PHONE

Pfizer Clinical Trials Contact Center

1-800-718-1021

BY EMAIL

Contact

[email protected]



Call Now